All articles
Rare disease
What does payer-informed evidence generation for rare disease therapies look like?
Drug pricing and affordability
FFS vs. MA utilization will impact relative net prices in negotiation
Drug pricing and affordability
Differences in Part B and D pricing for IPAY 2028 drugs
Coverage and payment
2027 supplemental benefits differ across Medicare Advantage plan types
Market and industry dynamics
How do Medicare Advantage and Medicare FFS utilization patterns differ?
Health equity
More than a reading test: rethinking health literacy through a behavioral science lens
Drug pricing and affordability
Changing the number of years to eligibility for Medicare negotiation significantly affects targeted drug spending
Drug pricing and affordability
IRA negotiation strategy: Projecting drug selection through MA and FFS spending dynamics
Healthcare delivery and transformation
State-level variation in site of care for Medicare beneficiaries treated for cancer
Quality improvement
A measure-level view of Medicare Advantage and fee-for-service quality performance